---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Economic burden and healthcare resource utilization. Topics: Company description of hospitalization and deferred tumor treatment in tumor hyperinsulinism, Hospitalization and continuous parenteral dextrose among expanded access patients (company filing), Inpatient days and parenteral glucose support in refractory malignant insulin-secreting tumors, Hospital stay after surgical resection versus endoscopic ultrasound-guided ablation of sporadic insulinoma, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Company description of hospitalization and deferred tumor treatment in tumor hyperinsulinism

> “Frequent prolonged hospitalization”
> “Leads to frequent deferral of tumor treatment”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.8.2-2"></a>

### Hospitalization and continuous parenteral dextrose among expanded access patients (company filing)

> “These patients have generally required continuous parenteral dextrose in order to prevent severe hypoglycemia and were typically hospitalized and in life-threatening or hospice-bound condition at the time of request.”
> “Further treatment with tumor-directed therapies (e.g., embolization, radiotherapy, chemotherapy) was often deferred as a result of debilitating hypoglycemia.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.1.8.2-3"></a>

### Inpatient days and parenteral glucose support in refractory malignant insulin-secreting tumors

> “Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.”
> “Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.”
> “Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.8.2-4"></a>

### Hospital stay after surgical resection versus endoscopic ultrasound-guided ablation of sporadic insulinoma

> “Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001).”

Source: [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/)

<a id="topic-2.2.1.8.2-5"></a>

### Postoperative length of stay after insulinoma resection (single center)

> “A retrospective analysis of 33 patients who had an insulinoma resected and who underwent routine postoperative monitoring of blood glucose”
> “The average postoperative length of hospital stay was 9 days”

Source: [Nockel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8058619/)

<a id="topic-2.2.1.8.2-6"></a>

### Admission for glucose monitoring around hepatic artery embolization of insulinoma liver metastases

> “The night before HAE, patients were admitted for blood glucose monitoring.”
> “Liver-directed therapies control tumor burden and address severe associated hypoglycemia symptoms, the latter of which require vigilance and careful meal timing on an outpatient basis.”

Source: [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)

<a id="topic-2.2.1.8.2-7"></a>

### Continuous intravenous support and cost of growth hormone therapy in non-islet cell tumor hypoglycemia (review)

> “However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.”
> “Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.”
> “Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases”
> “Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.1.8.2-8"></a>

### Cost-of-illness or claims-based cost studies of insulinoma or NICTH

No evidence found.

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
